Introduction
============

Recurrent pregnancy loss (RPL) is a frustrating, bitter experience to hopeful parents, estimated to occur in 2% to 4% for reproductive age couples \[[@B1]\]. PRL has been defined as three or more spontaneous pregnancy losses. In cases of female partner age over 35 years, history of infertility, normal karyotype on products of conception and embryonic heart activity observed in previous miscarriage, the investigation of causes of RPL have also been recommended even in women with two miscarriages. Nowadays, American Society for Reproductive Medicine proposes two more miscarriages as the RPL definition considering delayed pregnancy trial and late marital age \[[@B2]\]. However, European Society of Human Reproduction and Embryology maintains the definition of RPL as three or more miscarriages were happened. As an important public health concern, RPL may evoke physical and psychological traumas to pregnant women. Moreover, the risk of miscarriage in a subsequent pregnancy increases with the number of previous miscarriages \[[@B3]\]. There are still many debates regarding the diagnostic and treatment options. Various etiologies have been proposed including chromosomal abnormalities, uterine abnormalities, endocrine disease, autoimmune disease, alloimmune abnormalities, thrombophilia and infection. Despite extensive evaluation, 30% to 40% of cases of RPL remained unexplained \[[@B4][@B5]\]. Immune responses in maternal-fetal interface are important for survival of semi-allogenic fetus. Regarding the alloimmune tolerance, human leukocyte antigens, natural killer cells, TH1/TH2 cell imbalance, TH17 cells, regulatory T cells, macrophages and chemotactic factors have been investigated. Antiphospholid antibodies have been associated with RPL and other obstetric complications as thrombophilic disease \[[@B6]\]. Recently, there are many studies about the inherited thrombophilia such as factor V Leiden mutation \[[@B5]\], prothrombin gene mutation \[[@B3]\], plasminogen activator inhibitor-1 (PAI-1) gene polymorphism \[[@B7]\], methylenetetrahydrofolate reductase (MTHFR) polymorphism \[[@B8][@B9]\], protein S deficiency, protein C deficiency \[[@B10]\]. However, the results were inconsistent and also ethnical differences were existed \[[@B11]\]. The guideline for evaluation and management for RPL women based on the evidence and our circumstances is urgently needed. The goal of this study was to evaluate the etiologies and clinical outcomes of Korean RPL patients. And also, we investigated the differences between primary and secondary RPL patients, between two and three or more pregnancy losses.

Materials and methods
=====================

One hundred seventy eight women were enrolled after two or more miscarriages, who visited the RPL clinic at Dongsan Medical Center for last three years. Among them, 79 women had three or more miscarriages and 99 women had two miscarriages. One hundred forty five women suffered miscarriages without any live births were classified as primary RPL group, and compared with secondary RPL women. This prospective cohort study was approved by the University Institutional Review Board. All of the study populations were tested for chromosomal analysis, thyroid stimulating hormone (TSH), prolactin, blood glucose, PAI-1, natural killer (NK) cell proportion, anticardiolipin antibodies IgM/G, antiphospholipid antibodies IgM/G, lupus anticoagulant, anti-β2 glycoprotein-1 antibodies IgM/G, antinuclear antibody (ANA), protein C activity, protein S activity, antithrombin III activity, homocysteine, MTFHR gene polymorphism (C677G), factor V Leiden mutation and hysterosalphingography/or hysteroscopic evaluation. All patients took these tests at least two spontaneous menses after miscarriage. When the antiphospholipid antibodies including anticardiolipin and antiβ2glycoprotein-1 were positive, they were tested again at least 12 weeks apart.

Pregnancy outcomes after enrollment were evaluated. RPL patients were conceived naturally without the assisted reproductive technology such as intrauterine insemination or in-vitro-fertilization. Some patients who complained irregular cycle or anovulation took clomiphen citrate or aromatase inhibitor (Femara, Novartis AG, Stei, Switzerland) and had timed intercourse. RPL women took levothyroxine, bromocriptine, progesterone, low dose aspirin, low molecular weight heparin, steroid, or immunoglobulin as their conditions. Patients with hyperprolactinemia were treated with bromocriptine (Parlodel, Novartis AG, Annunziata, Italy) before pregnancy. Patients with hypothyroidism were treated with (Synthyroid, Bukwang, Ansan, Korea) before pregnancy and during pregnancy with monitoring the serum TSH and free T4 levels. Patients with elevated NK cell proportion were treated with prednisolone (Solondo, Yuhan, Cheongju, Korea) after confirming the urinary human chorionic gonadotropin until 12 gestational weeks with monitoring the NK cell proportion. When it was not controlled, immunoglobulin (400 mg/kg) was administrated every 3 weeks. Patients with antiphospholipid antibodies and thrombotic abnormalities such as protein S deficiencies were treated with low molecular weight heparin (Clexan, Sanofi Winthrop Industrie, le Trait, France; 40 mg) and low dose aspirin during the pregnancy. Most of women had multiple abnormalities, in that cases, combination of medication were applied.

Pregnancy loss was defined as any natural miscarriage occurring before 20 weeks of gestation. Ectopic pregnancy, molar pregnancy and artificial abortion were excluded.

For the statistical analysis, Student\'s *t*-test and Mann-Whitney test was performed using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) to determine the differences between primary and secondary RPL, and also between two and three or more miscarriages. For categorical data, Pearson\'s chi-square test and Fisher\'s exact test were used. Statistical significance was assumed at *P*\<0.05.

Results
=======

1. Demographic data and etiologic factors in RPL patients
---------------------------------------------------------

The mean age of RPL patients was 34.03±4.31 years, parity was 0.22±0.49 (range, 0 to 2) and mean number of miscarriages was 2.58±1.21 (range, 2 to 11). Twenty four of 178 women (13.5%) had anatomical cause such as uterine synnechia (14 cases), uterine anomaly (5 cases), endometrial polyp (4 cases), and submucosal myoma (1 case). Chromosomal abnormalities were 9 cases of balanced translocation and one Tuner syndrome, found in 8 women and 2 men among 178 couples (5.6%). Serum TSH was 2.43±1.78 mIU/mL (range, 0.01 to 10.54 mIU/mL), serum prolactin was 15.62±18.87 ng/mL (range, 3.48 to 174.81 ng/mL), fasting insulin levels was 6.96±5.86 µIU/mL (range, 1.44 to 34.13 µIU/mL). Serum PAI-1 was 26.99±21.58 ng/mL (range, 3.40 to 95.83 ng/mL). NK cells proportion was 14.56±7.38% (range, 2.40% to 41.60%). Serum homocysteine was 8.40±2.39 µmol/L (range, 3.85 to 22.99 µmol/L). Protein C activity was 109.13±21.83% (range, 10.705% to 171.00%), protein S activity was 71.52±24.14% (range, 15.00% to 170.00%), anti-thrombin III was 99.05±10.68% (range, 65.00% to 123.00%). Endocrine disorders (34.3%) such as hypothyrodism and hyperprolactinemia, and elevated NK cell proportion (43.3%) were observed. Antiphospholipid antibodies including anticardiolipin IgM/G, antiβ2glycoprotein-1 IgM/G, and lupus anticoagulant were observed in 7.3%. Deficiency of protein S activity was observed in 13.5%, however, deficiency of protein C and antithrombin III were observed only in 0.6% and 1.1% each. Factor V Leiden mutation was not found in any patients. MTFHR gene polymorphism was observed in 35.4% of RPL patients ([Table 1](#T1){ref-type="table"}).

Forty two women without any abnormal result after evaluation were classified as unexplained RPL (23.6%). Fifty women had single abnormality such as anatomical factor (9 cases), chromosomal factor (2 cases), endocrine factor (hypothyroidism 6 cases and hyperprolactinemia 5 cases), immunological factor (elevated NK cell 14 cases and autoantibodies 2 cases), and thrombotic factor (protein S deficiency 5 cases, hyperho-mocysteinemia 1 case, and MTFHR mutation 6 cases). Eighty six women (48.3%) had multiple abnormalities such as two factors (50 cases), three factors (28 cases) and even four factors (8 cases). The various combinations of etiologies were found.

2. Comparison of primary and secondary RPL patients
---------------------------------------------------

One hundred forty five women (81.5%) had not had a live birth before their miscarriages (primary RPL). The mean age of women with one or more prior live birth (35.45±4.91 years) was greater than that of women who had no prior live births (33.70±4.10 years, *P*=0.04). The mean parity of secondary RPL was 1.18±0.39. The number of miscarriages of each group were not different (2.66±1.14 for primary RPL and 2.79±0.99 for secondary RPL). Anatomical abnormalities and chromosomal abnormalities were found similarly in both groups. The mean value of TSH, prolactin, fasting insulin, blood glucose were not different between two groups. The incidence of endocrine disorders was similar in both groups. However, immunological abnormalities were more prevalent in primary RPL group compared to secondary RPL group (*P*=0.01). Elevated NK cell proportion was more common in primary RPL (49.7%) compared to that of secondary RPL (15.2%, *P*=0.01). Antiphospholipid antibodies and inherited thrombophilias were not different between two groups ([Table 2](#T2){ref-type="table"}).

3. Comparison of women with two miscarriages and women with three or more miscarriages
--------------------------------------------------------------------------------------

Seventy nine women (44.4%) had three or more miscarriages (range, 3 to 11) and 99 women had two miscarriages. The mean age of women with three or more miscarriages was similar with that of women with two miscarriages. The mean parity was not different between two groups either. Women with three or more RPL had more common anatomical abnormalities such as intrauterine adhesions (21.5%) compared to women with two RPL (7.1%, *P*=0.01). However, mean value of TSH, prolactin, fasting insulin, blood glucose, homocysteine, PAI-1, NK cell proportion, protein C activity, protein S activity, and antithrombin III activity in both groups were similar. Incidence of chromosomal abnormalities, endocrine disorders and immunological abnormalities were not different between two groups ([Table 3](#T3){ref-type="table"}).

4. Index pregnancy outcomes of RPL women
----------------------------------------

Among of 178 women, seventy seven women were pregnant. After management of those women, live birth rate was 84.4% and mean gestational weeks was 37.63±5.12 weeks. Twelve miscarriages were happened in the enrolled women. In primary RPL women, sixty three women out of 145 were pregnant, and live births were achieved in 51 women (81.0%). Fourteen women out of 33 secondary RPL women were pregnant, and all of them had live births. Secondary RPL women showed better live birth rate compared with primary RPL women, however, statistically insignificant. Delivery weeks of gestation were similar in both groups. Fifty one women with two previous miscarriages (51.5%) and 26 women with three or more miscarriages (32.9%) were pregnant. Compared with three or more RPL women, RPL women with two miscarriages showed higher pregnancy rate (*P*\<0.05). However, Live birth rates of each group were not different. Delivery weeks of gestation were not different either ([Table 4](#T4){ref-type="table"}).

Discussion
==========

Repeat pregnancy loss has been public health concern, developed 1 in 300 pregnancies and 2% to 4% of reproductive-aged couples. PRL has been defined as three or more spontaneous pregnancy losses. Nowadays, American Society for Reproductive Medicine proposes two more miscarriages as the RPL definition \[[@B2]\]. The comparison of etiologies or clinical outcomes between women with only two miscarriages and women with three or miscarriages is still scarce \[[@B1][@B12]\]. To our acknowledgment, this is the first study with Korean RPL women for comparison of the differences between primary and secondary RPL patients, between two and three or more pregnancy losses.

There is still a lack of consensus regarding the diagnostic and treatment options. However, patients have a strong will to perform diagnostic test and to start treatment despite a lack of solid evidence. Couples suffering RPL experienced emotional stress such as feeling of grief, lower self esteem, guilt, anger, depression and anxiety which persisted for 6 months after miscarriage \[[@B13]\]. Parental chromosome, uterine anatomy, endocrine disorder and antiphospholipid antibodies are undisputed etiology of RPL. However, 30% to 40% of RPL remained unexplained. Immunological imbalance, acquired and inherited thrombophilia have been issued as related with these unexplained RPL.

Only 5.6% of couples had chromosomal abnormalities, but chromosomal analysis must be considered a part of routine investigation. This result was consistent with other studies and fell within the reported range (2.5% to 8%) for women with RPL \[[@B1][@B14][@B15]\]. Uterine anatomic defects were found in 13.5%, similar with other reports \[[@B1][@B15]\]. Intrauterine adhesion was most common cause, followed by septated uterus. The prevalence of endocrine disorder in our study was 34.3%, higher than other report \[[@B4]\], most likely because of subclinical hypothyroidism. The abnormal level of TSH was defined as more than 2.5 µIU/mL instead of 4 µIU/mL. It has been recommended that the normal range of TSH for pregnancy are modified, and also some advocate using pregnancy thresholds for the treatment of women attempting conception in order to minimize the potential risks associated with subclinical hypothyroidism in pregnancy \[[@B16][@B17]\]. Thyroid hormone replacement with levothyroxine in pregnant women with subclinical hypothyroidism (TSH \>2.5 µIU/mL) improved pregnancy outcome \[[@B18][@B19]\]. The prevalence of hypothyroidism using levels of TSH more than 4 µIU/mL was similar with previous reports. Hyperprolactinemia is unique endocrinopathy that cause infertility and miscarriage through anovulation or luteal phase defect. Dopamine agonist like bromocriptine significantly improved subsequent pregnancy outcome in women with RPL and hyperprolactinemia \[[@B20]\]. Women with polycystic ovary syndrome, the most common endocrinopathy of reproductive-aged women, have an increased risk of pregnancy loss. The precise mechanism is unclear but possibly acts through the clotting factor PAI-1 \[[@B18]\]. In the meta-analysis about association between PAI-1 gene polymorphism and RPL, PAI-1-675G/A polymorphism was significantly associated with RPL (odds ratio \[OR\], 1.70; 95% confidence interval \[CI\], 1.21 to 2.38). Especially, this association was significant for Asians and Africans but not for American, Europeans, and Oceanians \[[@B7]\]. Management of polycystic ovary syndrome (PCOs) with normalization of weight or metformin seems to reduce the risk of pregnancy loss.

Peripheral blood and peri-implantation endometrial CD56^+^ NK cells in early pregnancy are intensively studied. Uterine natural killer cells in the endometrium are thought to support remodeling of the uterine spiral arteries and to facilitate successful placentation through the regulation of trophoblast invasion. An abnormal increase of the peripheral blood natural killer cell fraction and NK cytolytic activity is associated with RPL \[[@B21][@B22]\]. Downregulation of NK cells was associated with a favorable pregnancy outcome \[[@B23]\]. However, Immunotherapy for recurrent miscarriages and infertility is still controversial \[[@B24]\]. In our study, elevated peripheral NK cell was found in 77 women (43.3%), most common cause of enrolled RPL women. And also, antiphospholipid antibodies including anticardiolipin antibodies IgM/G, lupus anticoagulant, anti-β2 glycoprotein-1 antibodies IgM/G were found in 13 women (7.3%). Antiphospholipid syndrome (APS) is an autoimmune condition characterized by the production of antiphospholid antibodies combined with clinical features like vascular thrombosis or pregnancy morbidity \[[@B25]\]. The incidence of APS was reported as 15% to 20% in women with RPL \[[@B26][@B27]\], and fetal loss rate of these women was 50% to 90% if no specific treatment was given \[[@B6]\]. In this study, APS was less common than other studies. It is needed further large scale investigation for Korean RPL women. Treatment with heparin and aspirin is emerging as the therapy of choice, with approximately 75% of treated women having a successful live birth \[[@B26]\]. Screening for inherited thrombophilias such as factor V Leiden, prothrombin gene mutations, MTHFR gene polymorphism, protein C deficiencies, protein S deficiencies, and antithrombin deficiencies may have focused on recurrent miscarriages \[[@B5][@B28][@B29]\]. Factor V Leiden and prothrombin G20210A mutations are by far the most common of the inherited thrombophilias, present in 8 and 3%, respectively, of the general Caucasian population \[[@B1][@B30]\]. Protein S deficiency, protein c deficiency and antithrombin III deficiency were found 3.5%, 1.1%, and 1.5% each \[[@B1]\]. However, in Indian women with RPL, factor V Leiden mutation was found only 3.5% and proteins S deficiency was most common (16%) of the inherited thrombophilia \[[@B11]\]. In our study, factor V Leiden mutation was not found in any women and proteins S deficiency was found 13.5%. The risk of miscarriages related with inherited thrombophilia seems to be controversial. Recently, in meta-analysis, factor V Leiden mutation was associated with RPL (OR, 1.68; 95% CI, 1.16 to 2.44) \[[@B5]\]. A significant association was found between prothrombin mutation and RPL with OR 1.81 (95% CI, 1.26 to 2.60). In subgroup analysis, the pooled OR remained significant in European studies (OR, 1.80; 95% CI, 1.35 to 2.41), whereas it was not significant in the Middle-Eastern studies (OR, 2.39; 95% CI, 0.96 to 5.92) \[[@B3]\]. Inherited thrombophilia has shown the ethnical difference, which signify the need for consideration in screening and interpretation.

Compared to secondary RPL, women without any live birth had almost similar results in the evaluation tests. However, alloimmune abnormalities such as elevated NK cell proportions were more common in primary RPL. Shapira et al. \[[@B31]\] reported the only significant difference in the etiological evaluation was abnormal prolactin levels in the primary RPL. In our study, serum prolactin level and incidence of hyperprolactinemia were not different between two groups. Pregnancy rate and live birth rate were also similar. Miscarriages of index pregnancy tend to be happened in primary RPL group (12 out of 63) compared with none out of 33 in secondary RPL group, statistically insignificant. We believe further study with large scale is needed.

Women with three or more RPL compared to women with two RPL had also similar in the etiological evaluations except anatomical cause such as intrauterine adhesions. It might be related with previous uterine curettage. Bashiri et al. \[[@B12]\] reported women with two miscarriages and three or more miscarriages had very similar in evaluation test results and obstetric characteristics. In our study, pregnancy rate was significantly higher in women with two miscarriages (59.0%) than in women with three or more (33.3%, *P*=0.01). Live birth rate of each group was not different. Lund et al. \[[@B32]\]. reported the chance of a live birth by increasing number of miscarriages before first consultation was decreased, 70% for women with three miscarriages and 60% for five miscarriages until five years after consultation. Five years after the first consultation, overall cumulative live birth rates was achieved in 66.7% of women with RPL after management with imunoglobulin, steroid, progesterone, heparin, or aspirin \[[@B32]\]. Recently, Lee et al. \[[@B33]\]. reported overall live birth rate in Korean RPL women was 86.8%, regardless of treatment modalities such as low dose aspirin, low molecular weight heparin, or intravenous immunoglobulin. In our study, live birth in the index pregnancy was 84.4%, comparable with other studies. RPL patients have various etiologies, and most of them have multiple abnormalities. In our study, many RPL women were treated with combination of medication as their own conditions. We drew the overall live birth rate after combination of treatment which might be higher than live birth rate after singe treatment in other studies. Comparing primary RPL with secondary RPL, and two miscarriages with three or more, live birth rate of each groups were not different. However, women with secondary RPL might have better live birth rate even though the limited number of cases were not reached to statistical significance. Further longitudinal studies with larger scale are required.

The strength of present study is the prevalence of each etiologies and overall live birth rate in RPL women with primary or secondary, and two or three more miscarriages. We believe this study could be useful to counsel the RPL coupes. However, the limitation of this study was lack of the efficacy of each treatment. To establish the efficacy of each treatment precisely, women with single etiology without any other abnormalities are evaluated by randomized controlled trials. Considering the prevalence of RPL was 1% of general population, multicenter studies or national registration studies are needed.

In conclusion, immunological factor including autoimmune disorders and alloimmune disorders was most common etiology of RPL in our clinic. Inherited thrombophilia showed different patterns compared with other ethnic groups. Nowadays, the guideline for evaluation and management of RPL women based on the evidence and our Korean circumstances is urgently needed. Considering this situation, our data must be useful for counseling the RPL women and establishing the Korean RPL guidelines. Further well designed, large scaled studies are also needed.
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###### Demographic data and etiologic characteristics in all enrolled women with recurrent pregnancy losses (178 Enrolled women)
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Values are presented as mean±standard deviation or number (%). TSH, thyroid stimulating hormone; NK, natural killer; APA, antiphospholipid antibodies; FVL, factor V Leiden; MTFHR, methylenetetrahydrofolate reductase.

###### Comparison of demographic data and etiologic characteristics between primary and secondary recurrent pregnancy loss patients
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Values are presented as mean±standard deviation or number (%).

TSH, thyroid stimulating hormone; NK, natural killer; APA, antiphospholipid antibodies; FVL, factor V Leiden; MTFHR, methylenetetrahydrofolate reductase.

###### Comparison of demographic data and etiologic characteristics between women with two miscarriages and women with three or more miscarriages
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Values are presented as mean±standard deviation or number (%).

TSH, thyroid stimulating hormone; NK, natural killer; APA, antiphospholipid antibodies; FVL, factor V Leiden; MTFHR, methylenetetrahydrofolate reductase.

###### Index pregnancy outcomes of RPL women in each group
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Values are presented as mean±standard deviation or number (%).

RPL, recurrent pregnancy loss.
